KLF6 antibody - N-terminal region (ARP35640_P050)
- Known as:
- KLF6 (anti-) - N-terminal region (ARP35640_P050)
- Catalog number:
- arp35640_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- KLF6 antibody - N-terminal region (ARP35640_P050)
Related genes to: KLF6 antibody - N-terminal region (ARP35640_P050)
- Gene:
- KLF6 NIH gene
- Name:
- Kruppel like factor 6
- Previous symbol:
- BCD1, ST12, COPEB
- Synonyms:
- CPBP, GBF, Zf9, PAC1
- Chromosome:
- 10p15.2
- Locus Type:
- gene with protein product
- Date approved:
- 1997-10-16
- Date modifiied:
- 2016-10-05
Related products to: KLF6 antibody - N-terminal region (ARP35640_P050)
Related articles to: KLF6 antibody - N-terminal region (ARP35640_P050)
- Although PD-1/PD-L1 inhibitors are central to the management of advanced bladder cancer, most patients fail to achieve a meaningful response. While evidence ties MMT to fibrotic disease, its contribution to bladder cancer has yet to be examined. - Source: PubMed
Publication date: 2026/08/10
Chen YuwenWang ZihuanHe ChengwuYu ZheZhang JingeJiang FeifanZhang ZicaiLi TanghuaFu XinyangHou LinaLi Fei - - Source: PubMed
Publication date: 2026/08/08
Yu DongshengLi JiyeWei QianyiZhu ChunshengZhang XiaodanLi XiaopingGuo Danfeng - Using single-cell transcriptomics of bronchoalveolar lavage cells from /SIV co-infected rhesus macaques on cART, we reveal profound immune dysregulation during early SIV co-infection of latent tuberculosis. SIV induces a sharp decline in CD4 T cells, NK, and NKT cells, with incomplete recovery of -specific T effector responses despite viral suppression. Instead, a persistent T-skewed environment emerges, alongside sustained myeloid inflammation driven by Type I interferon signaling and pro-inflammatory regulators such as and . Ligand-receptor network analyses demonstrate expanded CD4 T cell-macrophage crosstalk and loss of immune homeostasis that cART fails to fully restore. These findings expose how SIV remodels the pulmonary immune landscape to impair protective immunity against , providing a transcriptomic framework to explain TB reactivation in HIV infection. Our work highlights the urgent need for adjunctive immunotherapies to complement cART, aiming to rebalance immune responses and improve TB control in co-infected individuals. - Source: PubMed
Publication date: 2026/07/27
Sharan RitiZou YiLai ZhaoWeldon KorriBradley ToddLuo XiWu HulinKhader Shabaana AKaushal Deepak - Lung cancer remains a leading cause of cancer-related mortality worldwide, with metastatic disease accounting for ∼90% of deaths. While p53 gene therapy offers promise for restoring tumor suppressor function, its clinical translation has been hindered by inefficient delivery systems and pulmonary administration challenges. Here, we developed redox-responsive thiolated chitosan nanoparticles (TCS NPs) as the first inhalable nanotherapeutic platform for tumor-selective p53 gene delivery to treat metastatic lung cancer. Our system exploits elevated glutathione levels in cancer cells to trigger selective gene release, while mucoadhesive properties ensure prolonged pulmonary retention. The p53 DNA-loaded TCS NPs demonstrated exceptional cancer selectivity, exhibiting significant cytotoxicity against lung cancer cells while maintaining biocompatibility with normal tissues. Treatment restored p53-mediated pathways, upregulating metastasis suppressors (KLF6 and E-cadherin) and apoptotic factors (Bax and cleaved caspase-3), thereby inhibiting migration, invasion, and metastatic progression. In vivo studies using ectopic xenograft and experimental metastasis models confirmed robust therapeutic efficacy, with inhaled TCS@p53 NPs achieving significant tumor suppression and reduced metastatic nodule formation while maintaining excellent safety profiles. This work presents a transformative inhalable gene therapy platform that overcomes traditional delivery limitations through tumor-selective targeting. - Source: PubMed
Publication date: 2026/07/24
Shim Yun SeopHan Sung MinJo Yun Kee - β-cell dysfunction is a key factor in the progression of diabetes. It was reported that lipotoxicity impaired β-cell mitochondrial function. However, the molecular mechanisms regulating lipotoxicity-induced β-cell mitochondrial dysfunction remain unclear. - Source: PubMed
Publication date: 2026/07/24
Wu LitingXiong QinZou FangYu PengYang YanlinXu ChangliuLiu JianpingLai XiaoyangGong Yingying